Sublingual Semaglutide-BPC 157 Combination for Weight Loss
Summary
The USPTO granted patent US12605427B2 to Red Mountain Med Spa LLC on April 21, 2026, covering sublingual Semaglutide compositions combined with Body Protection Compound-157 (BPC-157) for weight loss applications. The invention comprises sublingual tablets providing approximately 500 mcg or 750 mcg of Semaglutide in combination with 300 mcg of gastric peptide, designed to mitigate gastrointestinal side effects associated with Semaglutide monotherapy. The patent is based on application number 18317232 filed on May 15, 2023, with 6 claims granted.
What changed
USPTO issued patent US12605427B2 to Red Mountain Med Spa LLC on April 21, 2026, covering a novel sublingual composition combining Semaglutide with BPC-157 (Body Protection Compound-157), a gastric pentapeptide. The patent discloses that the addition of BPC-157 addresses gastrointestinal side effects commonly associated with Semaglutide, a GLP-1 receptor agonist. The composition is formulated as sublingual tablets, with preferred dosage units delivering 500 mcg or 750 mcg Semaglutide alongside 300 mcg BPC-157. The patent application was filed on May 15, 2023, and contains 6 claims.
For pharmaceutical manufacturers developing GLP-1-based weight loss therapies, this patent represents potential freedom-to-operate considerations. The combination approach of Semaglutide with BPC-157 in sublingual formulation may present opportunities for differentiation in the competitive weight management pharmaceutical market. Generic or biosimilar developers should conduct clearance analyses before entering this space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Sublingual semaglutide-BPC 157 combination for weight loss
Grant US12605427B2 Kind: B2 Apr 21, 2026
Assignee
RED MOUNTAIN MED SPA, LLC
Inventors
Suzanne Bentz, Austin Lucht, Shelly Kocher
Abstract
Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.
CPC Classifications
A61K 38/26 A61K 9/006 A61K 9/2009 A61K 9/2013 A61K 9/2018 A61K 9/2027 A61K 38/10
Filing Date
2023-05-15
Application No.
18317232
Claims
6
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.